16 studies found for:    MACULAR DEGENERATION, AGE-RELATED, 6
Show Display Options
Rank Status Study
1 Completed Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration
Conditions: Age-Related Maculopathy;   Age-Related Maculopathies;   Eye Diseases;   Retinal Degeneration;   Macular Degeneration
Interventions: Biological: RN6G;   Biological: Placebo
2 Completed Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
Conditions: Age-Related Maculopathy;   Age-Related Maculopathies;   Eye Diseases;   Retinal Degeneration;   Macular Degeneration
Interventions: Biological: RN6G;   Biological: Placebo
3 Recruiting Omega 6:Omega 3 Ratio and Progression of Age-related Macular Degeneration (AMD).
Condition: Age-related Macular Degeneration
Intervention:
4 Terminated Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
Condition: Age-Related Maculopathy
Interventions: Biological: RN6G;   Biological: Placebo
5 Unknown  A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
Condition: Age-Related Macular Degeneration (AMD)
Intervention: Drug: pegaptanib sodium (Macugen)
6 Completed Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL;   Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL;   Other: Anecortave Acetate Vehicle
7 Completed Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration
Condition: Wet Age-Related Macular Degeneration
Intervention: Drug: ACZ885
8 Completed Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
Condition: Age-Related Macular Degeneration
Intervention: Drug: pegaptanib sodium (Macugen)
9 Terminated Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
Condition: Age-Related Macular Degeneration
Interventions: Drug: Photodynamic Therapy (PDT) with Visudyne (verteporfin);   Drug: Macugen (pegaptanib sodium)
10 Completed A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
Condition: Age-Related Macular Degeneration
Intervention: Drug: Pegaptanib sodium
11 Completed Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: pegaptanib sodium
12 Terminated A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: Pegaptanib sodium
13 Completed
Has Results
Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
Condition: Macular Degeneration
Intervention: Drug: pegaptanib sodium (Macugen)
14 Recruiting Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium
Conditions: Age-Related Macular Degeneration;   Retinal Vein Occlusion;   Diabetic Macular Edema
Intervention: Drug: pegaptanib sodium injection
15 Recruiting Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
Condition: Visual Impairment Due to Neovascular AMD
Interventions: Drug: Ranibizumab;   Drug: Aflibercept
16 Completed
Has Results
Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
Condition: Polypoidal Choroidal Vasculopathy
Interventions: Drug: Verteporfin Photodynamic Therapy;   Drug: Ranibizumab

Indicates status has not been verified in more than two years